Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Prothena Corporation plc - Ordinary Shares
(NQ:
PRTA
)
7.430
+0.330 (+4.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Prothena Corporation plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Beyond The Numbers: 7 Analysts Discuss Prothena Corp Stock
May 09, 2025
Via
Benzinga
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
May 09, 2025
Via
Benzinga
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
May 08, 2025
From
Prothena Corporation plc
Via
Business Wire
Earnings Scheduled For May 8, 2025
May 08, 2025
Via
Benzinga
A Look Ahead: Prothena Corp's Earnings Forecast
May 07, 2025
Via
Benzinga
Prothena to Report First Quarter 2025 Financial Results on May 8
May 01, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
February 24, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
February 20, 2025
Via
Benzinga
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
February 26, 2025
Via
Benzinga
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
February 20, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
February 13, 2025
From
Prothena Corporation plc
Via
Business Wire
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings)
February 07, 2025
Via
Benzinga
Demystifying Prothena Corp: Insights From 6 Analyst Reviews
December 20, 2024
Via
Benzinga
Expert Ratings For Prothena Corp
November 13, 2024
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Earnings Preview For Prothena Corp
November 11, 2024
Via
Benzinga
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
January 28, 2025
Via
Benzinga
Prothena Announces Board of Directors Update
December 30, 2024
From
Prothena Corporation plc
Via
Business Wire
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
December 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
December 19, 2024
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients.
Via
Investor's Business Daily
Breaking Down Prothena Corp: 4 Analysts Share Their Views
October 01, 2024
Via
Benzinga
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
December 19, 2024
Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses.
Via
Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
December 19, 2024
Via
Benzinga
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
December 19, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Third Quarter 2024 Financial Results on November 12
November 05, 2024
From
Prothena Corporation plc
Via
Business Wire
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
October 28, 2024
Via
Benzinga
Dow Dips 300 Points; Emcore Shares Spike Higher
September 30, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
September 30, 2024
Via
Benzinga
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
September 30, 2024
Via
Benzinga
Exposures
Fossil Fuels
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.